Navtemadlin
- Generic Name
- Navtemadlin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H35Cl2NO5S
- CAS Number
- 1352066-68-2
- Unique Ingredient Identifier
- 7R7G6EH5UL
- Background
Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT06479135
- Locations
- 🇺🇸
Mission Cancer + Blood, Des Moines, Iowa, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 268
- Registration Number
- NCT05797831
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸Texas Oncology-San Antonio Medical Center, San Antonio, Texas, United States
🇺🇸Kaiser Permanente Center, Vallejo, California, United States
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Registration Number
- NCT05705466
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT04190550
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT03217266
- Locations
- 🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States
🇺🇸CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT03107780
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT03041688
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT03031730
- Locations
- 🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸University of Texas at Austin, Austin, Texas, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT02825836
- Locations
- 🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇵🇱Pratia MCM Krakow, Krakow, Poland
🇵🇱Szpital Wojewódzki, Opole, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.